Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.62
TBPH's Cash-to-Debt is ranked lower than
74% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. TBPH: 1.62 )
Ranked among companies with meaningful Cash-to-Debt only.
TBPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.62  Med: No Debt Max: No Debt
Current: 1.62
Equity-to-Asset 0.44
TBPH's Equity-to-Asset is ranked lower than
70% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TBPH: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
TBPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.69  Med: 0.84 Max: 0.89
Current: 0.44
-0.69
0.89
Piotroski F-Score: 3
Altman Z-Score: 0.76
Beneish M-Score: -4.49
WACC vs ROIC
14.23%
-263.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -686.41
TBPH's Operating Margin % is ranked lower than
70% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. TBPH: -686.41 )
Ranked among companies with meaningful Operating Margin % only.
TBPH' s Operating Margin % Range Over the Past 10 Years
Min: -69152.21  Med: -431.8 Max: -7.36
Current: -686.41
-69152.21
-7.36
Net Margin % -742.60
TBPH's Net Margin % is ranked lower than
72% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. TBPH: -742.60 )
Ranked among companies with meaningful Net Margin % only.
TBPH' s Net Margin % Range Over the Past 10 Years
Min: -69152.21  Med: -432.56 Max: -7.36
Current: -742.6
-69152.21
-7.36
ROE % -77.39
TBPH's ROE % is ranked lower than
68% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. TBPH: -77.39 )
Ranked among companies with meaningful ROE % only.
TBPH' s ROE % Range Over the Past 10 Years
Min: -173.81  Med: -68.39 Max: -64.27
Current: -77.39
-173.81
-64.27
ROA % -46.54
TBPH's ROA % is ranked lower than
63% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. TBPH: -46.54 )
Ranked among companies with meaningful ROA % only.
TBPH' s ROA % Range Over the Past 10 Years
Min: -1241.48  Med: -93.88 Max: -40.6
Current: -46.54
-1241.48
-40.6
ROC (Joel Greenblatt) % -2040.75
TBPH's ROC (Joel Greenblatt) % is ranked lower than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. TBPH: -2040.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TBPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3053.02  Med: -1687.58 Max: -1032.75
Current: -2040.75
-3053.02
-1032.75
3-Year Revenue Growth Rate 437.70
TBPH's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. TBPH: 437.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TBPH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -33  Med: 202.35 Max: 437.7
Current: 437.7
-33
437.7
3-Year EBITDA Growth Rate -6.70
TBPH's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. TBPH: -6.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TBPH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.7  Med: 95.2 Max: 197.1
Current: -6.7
-6.7
197.1
3-Year EPS without NRI Growth Rate -4.70
TBPH's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. TBPH: -4.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TBPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.7  Med: 78.2 Max: 161.1
Current: -4.7
-4.7
161.1
GuruFocus has detected 3 Warning Signs with Theravance Biopharma Inc $TBPH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TBPH's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TBPH Guru Trades in Q3 2016

Seth Klarman 7,350,991 sh (unchged)
Chuck Royce 118,800 sh (-55.29%)
» More
Q4 2016

TBPH Guru Trades in Q4 2016

Joel Greenblatt 9,571 sh (New)
Steven Cohen 170,700 sh (New)
Seth Klarman 9,273,991 sh (+26.16%)
Chuck Royce 103,300 sh (-13.05%)
» More
Q1 2017

TBPH Guru Trades in Q1 2017

Chuck Royce 103,300 sh (unchged)
Seth Klarman 9,273,991 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 90,700 sh (-46.87%)
» More
Q2 2017

TBPH Guru Trades in Q2 2017

Seth Klarman 9,273,991 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 93,300 sh (-9.68%)
» More
» Details

Insider Trades

Latest Guru Trades with TBPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-03-31 Sold Out $28.28 - $37.06 $ 27.70-13%0
Seth Klarman 2016-12-31 Add 26.16%0.81%$24.57 - $38.58 $ 27.70-11%9,273,991
Joel Greenblatt 2016-12-31 New Buy$24.57 - $38.58 $ 27.70-11%9,571
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BGNE » details
Traded in other countries:0TB.Germany,
Headquarter Location:Cayman Islands
Theravance Biopharma Inc is a diversified biopharmaceutical company. It is engaged in discovery, research, development and commercialization of human therapeutics.

Theravance Biopharma is a diversified biotechnology company that creates medicines to treat serious illnesses. The company's research and development are concentrated primarily on four therapeutic areas-infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease. Its commercial infrastructure is focused primarily on the acute care setting. The company uses strategic collaboration with other industry players. Theravance generates the majority of its revenue in the U.S. and Europe, followed by Asia.

Top Ranked Articles about Theravance Biopharma Inc

Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update
Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
Theravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August 8, 2017
Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS

Ratios

vs
industry
vs
history
PB Ratio 6.13
TBPH's PB Ratio is ranked lower than
74% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. TBPH: 6.13 )
Ranked among companies with meaningful PB Ratio only.
TBPH' s PB Ratio Range Over the Past 10 Years
Min: 1.5  Med: 2.68 Max: 9.42
Current: 6.13
1.5
9.42
PS Ratio 42.56
TBPH's PS Ratio is ranked lower than
78% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. TBPH: 42.56 )
Ranked among companies with meaningful PS Ratio only.
TBPH' s PS Ratio Range Over the Past 10 Years
Min: 10.34  Med: 27 Max: 262.52
Current: 42.56
10.34
262.52
EV-to-EBIT -6.41
TBPH's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. TBPH: -6.41 )
Ranked among companies with meaningful EV-to-EBIT only.
TBPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.9  Med: -2.7 Max: -0.8
Current: -6.41
-9.9
-0.8
EV-to-EBITDA -6.53
TBPH's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. TBPH: -6.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
TBPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.1  Med: -2.8 Max: -0.8
Current: -6.53
-10.1
-0.8
Current Ratio 6.74
TBPH's Current Ratio is ranked higher than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. TBPH: 6.74 )
Ranked among companies with meaningful Current Ratio only.
TBPH' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 6.79 Max: 10.73
Current: 6.74
0.38
10.73
Quick Ratio 6.53
TBPH's Quick Ratio is ranked higher than
74% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. TBPH: 6.53 )
Ranked among companies with meaningful Quick Ratio only.
TBPH' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 6.57 Max: 10.48
Current: 6.53
0.1
10.48
Days Inventory 1.00
TBPH's Days Inventory is ranked higher than
97% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. TBPH: 1.00 )
Ranked among companies with meaningful Days Inventory only.
TBPH' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 1032.22 Max: 1401.54
Current: 1
1
1401.54
Days Sales Outstanding 15.66
TBPH's Days Sales Outstanding is ranked higher than
87% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. TBPH: 15.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
TBPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.85  Med: 12.84 Max: 321.39
Current: 15.66
4.85
321.39
Days Payable 686.29
TBPH's Days Payable is ranked higher than
94% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. TBPH: 686.29 )
Ranked among companies with meaningful Days Payable only.
TBPH' s Days Payable Range Over the Past 10 Years
Min: 218.57  Med: 892.35 Max: 1473.79
Current: 686.29
218.57
1473.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.80
TBPH's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. TBPH: -17.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TBPH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.8  Med: -12 Max: -6.2
Current: -17.8
-17.8
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 24.99
TBPH's Price-to-Net-Cash is ranked lower than
79% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. TBPH: 24.99 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TBPH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.32  Med: 5.39 Max: 35.81
Current: 24.99
2.32
35.81
Price-to-Net-Current-Asset-Value 18.01
TBPH's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. TBPH: 18.01 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TBPH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.83  Med: 3.45 Max: 25.81
Current: 18.01
1.83
25.81
Price-to-Tangible-Book 6.14
TBPH's Price-to-Tangible-Book is ranked lower than
65% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. TBPH: 6.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TBPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.66  Med: 2.67 Max: 8.8
Current: 6.14
1.66
8.8
Price-to-Median-PS-Value 1.58
TBPH's Price-to-Median-PS-Value is ranked lower than
84% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. TBPH: 1.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TBPH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.05 Max: 9.01
Current: 1.58
0.34
9.01
Earnings Yield (Greenblatt) % -15.62
TBPH's Earnings Yield (Greenblatt) % is ranked lower than
55% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. TBPH: -15.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TBPH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -123  Med: -36.5 Max: -10.1
Current: -15.62
-123
-10.1

More Statistics

Revenue (TTM) (Mil) $31.36
EPS (TTM) $ -4.67
Beta2.17
Short Percentage of Float40.39%
52-Week Range $23.15 - 43.44
Shares Outstanding (Mil)53.83

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -4.64 -4.10
EPS without NRI ($) -4.64 -4.10
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for TBPH

Headlines

Articles On GuruFocus.com
Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Updat Aug 08 2017 
Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Tri Aug 08 2017 
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) Aug 02 2017 
Theravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August 8 Aug 01 2017 
Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Developmen Jul 31 2017 
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revef Jul 19 2017 
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revef Jul 19 2017 
New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Tr Jun 05 2017 
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several P May 23 2017 
Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several P May 23 2017 

More From Other Websites
See what the IHS Markit Score report has to say about Theravance Biopharma Inc. Aug 23 2017
Edited Transcript of TBPH earnings conference call or presentation 8-Aug-17 9:00pm GMT Aug 13 2017
Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business... Aug 08 2017
Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical... Aug 08 2017
Investor Network: Theravance Biopharma Inc to Host Earnings Call Aug 08 2017
Corporate News Blog - Theravance Biopharma’s Velusetrag Successful in Mid-Stage Gastroparesis... Aug 04 2017
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108)... Aug 02 2017
Theravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August... Aug 01 2017
Theravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : July 31, 2017 Jul 31 2017
Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate... Jul 31 2017
ETFs with exposure to Theravance Biopharma, Inc. : July 25, 2017 Jul 25 2017
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of... Jul 19 2017
Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : July... Jul 17 2017
Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : June... Jun 15 2017
Theravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound? Jun 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}